Editorial Board
(Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 29, 2023 Category: Cancer & Oncology Source Type: research
Desmoid-type fibromatosis: Current Therapeutic Strategies and Future Perspectives
Desmoid tumors (DT), also known as aggressive fibromatosis or deep fibromatosis are rare mesenchymal neoplasms that are considered locally invasive with significant morbidity and mortality. [1 –2] DT are extremely rare, with a reported incidence of 2-4 per million population and account for only 0.03% of all diagnosed neoplasms. [3–4] They are more frequent among female patients and most commonly develop in patients between the ages of 15 and 60 years. [5] They most commonly occur in the abdominal wall, mesentery or the extremities. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 25, 2023 Category: Cancer & Oncology Authors: Rebecca IBRAHIM, Tarek ASSI, Rita Khoury, Carine NGO, Matthieu Faron, Benjamin Verret, Antonin L évy, Charles Honoré, Clémence Hénon, Cécile Le Péchoux, Ratislav Bahleda, Axel Le Cesne Tags: Anti-tumour Treatment Source Type: research
Neoadjuvant chemotherapy for early-stage colon cancer
Colorectal cancer (CRC) is the 3rd most commonly diagnosed tumour and the 2nd leading cause of cancer-related deaths worldwide, with colonic tumours accounting for about two thirds of all these cases (1). Approximately 80% of patients are diagnosed with early-stage disease (2). In this setting, surgical resection is the mainstay of treatment, with 5-year survival rates of approximately 99% for stage I, 80% for stage II, and 50% for stage III cancers (3,4). (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 22, 2023 Category: Cancer & Oncology Authors: Alessandro Audisio, Roberta Fazio, Valentina Dapr à, Irene Assaf, Alain Hendlis, Francesco Sclafani Tags: Hot Topic Source Type: research
Histology independent drug development – is this the future for cancer drugs?
This White Paper has been developed following the Cancer Drug Development Forum (CDDF) ’s ‘Histology independent drug development – is this the future for cancer drugs?’ workshop, which took place on 14-15th November, 2022, in Amsterdam. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 22, 2023 Category: Cancer & Oncology Authors: Lucinda Billingham, Lynn Brown, Theodor Framke, Alastair Greystoke, Eivind Hovig, Siddhartha Mathur, Philippe Page, Elias Pean, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Richardus Vonk, Sacha Wissink, Hilke Zander, Ruth Plummer Tags: Hot Topic Source Type: research
The State of the Art of EGFR exon 20 insertions in non-small cell lung cancer: diagnosis and future perspectives
Lung cancer (LC) is the leading cause of cancer-related mortality worldwide, and, although smoking is the most frequent cause of LC, 10-15% of all LCs are diagnosed in never-smokers.[1] Treatment of actionable mutations in about 60% of non-small cell lung cancer (NSCLC) marked the era of precision medicine with the use of a whole generation of targeted therapies that have dramatically improved patient prognosis.[2] (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 19, 2023 Category: Cancer & Oncology Authors: Miriam Dorta-Su árez, Maria de Miguel, Oscar Amor-Carro, José Miguel Calderón, MCarmen González-Ortega, Delvys Rodríguez-Abreu Tags: Tumour Review Source Type: research
Phase to Phase: Navigating Drug Combinations with Hypomethylating Agents in Higher-risk MDS Trials for Optimal Outcomes
Management of myelodysplastic neoplasms (MDS) is a multifaceted challenge that requires a personalized approach, aimed at enhancing both the quality of life and longevity for each patient. Considering the broad heterogeneity in clinical outcomes, it is crucial to adopt a personalized, patient-centered treatment approach and for assessment of therapy success [1]. Risk stratification with the Revised International Prognostic Scoring System (IPSS-R) classifies patients into two primary categories, lower-risk MDS (LR MDS) and higher-risk MDS (HR MDS) [2 –3]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 18, 2023 Category: Cancer & Oncology Authors: Almuth Maria Anni Merz, Marie Sebert, Jan Sonntag, Anne Sophie Kubasch, Uwe Platzbecker, Lionel Ad ès Tags: Tumour Review Source Type: research
Breaking barriers in Triple Negative Breast Cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)
Triple-negative breast cancer (TNBC) is defined by the lack of expression of estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) on tumor cells. It accounts for 15-20% of newly diagnosed breast cancer (BC) cases and is distinguished by the least favorable prognosis among BC subtypes, along with a long-standing paucity of effective therapeutic options.[1,2] In the past few years, research breakthroughs have brought to light the significance of the TNBC microenvironment heterogeneity, revealing a dynamic relationship with cancer cell features and emphasizing the need for a...
Source: Cancer Treatment Reviews - December 14, 2023 Category: Cancer & Oncology Authors: Arianna Dri, Grazia Arpino, Giampaolo Bianchini, Giuseppe Curigliano, Romano Danesi, Michelino De Laurentiis, Lucia Del Mastro, Alessandra Fabi, Daniele Generali, Alessandra Gennari, Valentina Guarneri, Daniele Santini, Edda Simoncini, Claudio Zamagni, Fa Tags: New Drugs Source Type: research
MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action
Liposarcomas (LPS) are rare mesenchymal neoplasms that arise from lipocytes in soft tissues. LPS account for approximately 15% to 20% of all soft tissue sarcomas in adults [1,2]. LPS may arise in any anatomic site; the most common locations are the retroperitoneum and extremities [3,4]. In 2016, the incidence of liposarcoma in the United States was approximately 1 per 100,000 person-years [3]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 8, 2023 Category: Cancer & Oncology Authors: Neeta Somaiah, William Tap Tags: Tumour Review Source Type: research
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
Breast cancer (BC) is the most common malignancy worldwide among women [1]. While earlier detection and improved treatments have contributed to BC mortality decline since the 1990s [2], it remains the leading cause of mortality among women, causing 685,000 deaths globally in 2020 [1]. The 2018 American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) guidelines categorize BC as hormone receptor-positive (HR+; tumors with> 10% of cells staining positive for estrogen receptors [ERs] and/or progesterone receptors [PRs] by immunohistochemistry [IHC]; 1 –10% cell staining is considered “low positive...
Source: Cancer Treatment Reviews - December 8, 2023 Category: Cancer & Oncology Authors: Komal Jhaveri, Frederik Marm é Tags: Tumour Review Source Type: research
Combination Therapies in Patients with Favorable Risk Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
In recent years, there have been significant advancements in the treatment of metastatic renal cell carcinoma (mRCC) with the introduction of combination therapies involving immunotherapy (IO). Particularly, the combination of nivolumab and ipilimumab has demonstrated noteworthy improvements in overall survival (OS) when compared to sunitinib in patients classified as intermediate- and poor-risk according to the “International mRCC Database Consortium (IMDC).” These findings highlight the promising potential of IO-based combination therapies in the management of mRCC [1]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 8, 2023 Category: Cancer & Oncology Authors: Hatice Bolek, Emre Yeked üz, Yüksel Ürün Tags: Systematic or Meta-analysis Studies Source Type: research
Neoadjuvant therapy in Hormone Receptor-Positive/HER2-Negative Breast Cancer
Breast cancer is a leading cause of mortality and morbidity worldwide. In countries where early detection programs are implemented, approximately 90-95% of patients with breast cancer (BC) present with localized disease[1]. Hormone-receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC, defined by the immunohistochemical expression of oestrogen (ER) and/or progesterone (PR) receptor, represents the most common subtype, encompassing at least two-thirds of all new diagnoses [2-4]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 8, 2023 Category: Cancer & Oncology Authors: Luca Cantini, Dario Trapani, Lorenzo Guidi, Luca Boscolo Bielo, Roberta Scafetta, Marcin Koziej, Laura Vidal, Kamal S. Saini, Giuseppe Curigliano Source Type: research
acccaaaccMDM2-p53 in Liposarcoma: The Need for Targeted Therapies With Novel Mechanisms of Action
Liposarcomas (LPS) are rare mesenchymal neoplasms that arise from lipocytes in soft tissues. LPS account for approximately 15% to 20% of all soft tissue sarcomas in adults [1,2]. LPS may arise in any anatomic site; the most common locations are the retroperitoneum and extremities [3,4]. In 2016, the incidence of liposarcoma in the United States was approximately 1 per 100,000 person-years [3]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - December 8, 2023 Category: Cancer & Oncology Authors: Neeta Somaiah, William Tap Tags: Tumour Review Source Type: research
Reporting of Post-protocol Therapies in Metastatic Breast Cancer Registration Clinical Trials: A Systematic Review
The treatment for metastatic breast cancer (MBC) is constantly evolving, with 36 new indications for 18 different drugs approved by the US FDA in the last decade [1]. Clinical trials are vital for exploring new therapies and improving patient outcomes. Patients with MBC are usually treated with multiple sequential lines of therapy[2]. Often, there is no consensus regarding optimal sequencing of treatment, leading to potential variation in post-protocol therapies of patients following progression on clinical trials. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - November 30, 2023 Category: Cancer & Oncology Authors: Shlomit Strulov Shachar, Yasmin Korzets, Daniel Shepshelovich, Noa Zlothover, Eitan Amir, Ariadna Tibau, Hadar Goldvaser Tags: Systematic or Meta-analysis Studies Source Type: research
Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors
The successful uptake of immune checkpoint inhibitors (ICIs) for cancer treatment is illustrated by the increasing number of tumour types and treatment settings for which these treatments have proven efficacy (1 –4). To date, ICIs are standard of care for multiple types of cancer and are used in different treatment settings, i.e., palliative, adjuvant and neoadjuvant (1,5,6). Although ICIs can induce a remarkable durable tumour response, only a subset of patients experience clinical benefit from treatment with ICIs (7). (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - November 27, 2023 Category: Cancer & Oncology Authors: Karlijn de Joode, Niels Heersche, Edwin A. Basak, Sander Bins, Astrid A.M. van der Veldt, Ron H.N. van Schaik, Ron H.J. Mathijssen Source Type: research
Clinical application of cytokine-induced killer (CIK) cell therapy in colorectal cancer: current strategies and future challenges
Definition (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - November 27, 2023 Category: Cancer & Oncology Authors: Celine Man Ying Li, Runhao Li, Paul Drew, Timothy Price, Eric Smith, Guy J. Maddern, Yoko Tomita, Kevin Fenix Tags: Anti-tumour Treatment Source Type: research
